Viiv Healthcare

This early-stage study tests a new lab-made antibody called VH4527079 in healthy adults and people with HIV. The goal is to check if it is safe and how the body handles it when given as a shot or through an IV. About 102 participants will receive one or more doses, and researcher…

This study tested whether people with HIV who are already well-controlled on daily pills could switch to a once-monthly injection of two long-acting drugs (cabotegravir and rilpivirine). About 618 adults with suppressed HIV took part. The goal was to see if the shots work just as…

This study looks at two different HIV treatments for people who have never taken HIV medication before. Everyone starts with a daily pill (Dolutegravir/Lamivudine) to lower the virus to undetectable levels. Once that happens, participants can choose to either stay on the daily pi…

This early-stage study tests whether adding an experimental drug (VH3810109) with or without another drug (fostemsavir) to standard HIV therapy can reduce the amount of hidden HIV in the body. The study involves 107 adults with HIV, including those new to treatment and those alre…

This study tested whether adults with HIV whose virus is already suppressed can switch from taking daily pills to getting a monthly injection of two long-acting drugs (cabotegravir and rilpivirine). Over 600 participants were enrolled. The goal was to see if the shots keep the vi…

This study tests a new drug combination (VH3810109 plus cabotegravir) for adults with HIV whose virus is already well-controlled by standard medication. The goal is to see if this new approach can keep the virus suppressed as effectively as current treatments. About 185 participa…

This study tests whether a two-drug HIV pill (dolutegravir/lamivudine) works as well as a three-drug pill (bictegravir/emtricitabine/tenofovir alafenamide) for adults who have never taken HIV medication before. About 473 participants will take one of the two pills daily for up to…

This study tests a new version of the HIV prevention drug cabotegravir, given as a shot every 4 months. About 229 teens and adults at risk of HIV will receive the injection to see if drug levels stay high enough to prevent infection and to check for side effects. The goal is to m…

This study looks at how healthy adults without HIV tolerate two long-acting injections used to prevent or treat HIV. Researchers are checking injection site reactions and how acceptable participants find the shots. The goal is to understand comfort and side effects, not to treat …

This early-stage study tests the safety and how the body handles a new type of HIV drug called a capsid inhibitor. It involves 85 healthy adults who receive either the drug or a placebo as a shot under the skin or into a muscle. The goal is not to treat HIV, but to gather importa…